Omigapil

Omigapil (CGP3466B free base), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil has the potential for the research of Alzheimer's disease. Omigapil is a apoptosis inhibitor. Omigapil can be used for the research of congenital muscular dystrophy (CMD) . Omigapil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].

Product Specifications

CAS Number

[181296-84-4]

Product Name Alternative

CGP3466B (free base) ; TCH346

UNSPSC

12352005

Target

Apoptosis

Related Pathways

Apoptosis

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Solubility

10 mM in DMSO

Smiles

C#CCN(CC1=CC2=C(OC3=C1C=CC=C3)C=CC=C2)C

Molecular Formula

C19H17NO

Molecular Weight

275.34

References & Citations

[1]Sarina Meinen, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3 (8) :465-79.|[2]Tanusree Sen, et al. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11 (522) :eaao6765.